Altrichter S, Staubach P, Pasha M, Singh B, et al. An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria. J Allergy Clin Immunol 2022;149:1683-1690.
PMID: 34954198